This aims to streamline processes, ensure synergies and avoid duplication of work within the network.

the European medicines agencies network strategy to 2025.It is designed to function as a ' supply and availability hub', tracking progress on the medicine availability and shortage-related activities that the European medicines regulatory network is undertaking under the following EU projects: It does not cover non-authorised medicines.

The Task Force focuses on the availability of authorised human and veterinary medicines, irrespective of the authorisation route. The HMA / EMA Task Force on the Availability of Authorised Medicines for Human and Veterinary Use is providing strategic and structural solutions to tackle disruptions in the supply of medicines and ensure their continued availability in the EU.